Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen IV busulfan (Bu) (130 mg/m(2))-IV fludarabine (Flu) (40 mg/m(2)) is associated with low morbidi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biol Blood Marrow Transplant
Asıl Yazarlar: Alatrash, Gheath, de Lima, Marcos, Hamerschlak, Nelson, Pelosini, Matteo, Wang, Xuemei, Xiao, Lianchun, Kerbauy, Fabio, Chiattone, Alexandre, Rondon, Gabriela, Qazilbash, Muzaffar H., Giralt, Sergio A., de Padua Silva, Leandro, Hosing, Chitra, Kebriaei, Partow, Zhang, Weiqing, Nieto, Yago, Saliba, Rima M., Champlin, Richard E., Andersson, Borje S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4261630/
https://ncbi.nlm.nih.gov/pubmed/21338705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.02.007
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller